Nanolive SA closes a series C round at $22.2 million
Share this article
After the successful closing of a US $22.2 million Series C equity financing, Nanolive announces the appointment of two extraordinary women to its board of directors: Dr. Deborah Birx and Mrs. Victoria Wang.
Nanolive, based in canton de Vaud (Switzerland), develops cutting edge state-of-the-art label-free live cell digital analytical solutions to provide researchers and scientists working in the biopharmaceutical industry and laboratories with all the tools required to accelerate innovation in growth industries such as drug discovery and cell therapy.
The investment round was led by an affiliate of Innoviva, a US-based NASDAQ-listed life science company, and Taiwania Capital, a leading life science venture capital company based in Taiwan and active in San Francisco and Boston.
Dr. Deborah Birx and Victoria Wang join the Board of Directors
Dr. Deborah Birx is an American physician, scientist, and diplomat. She served as the Director of the Division of Retroviral Research in DoD from 1995-2005, Director of Centers for Disease Control and Prevention’s Division of Global HIV/AIDS (DGHA) from 2005 to 2014, Director of the U.S. response to HIV/AIDS overseeing $6 billion investment annually 2014-2021, U.S. lead board member to the Global Fund 2014-2021, and served the United States as the White House Coronavirus Response Coordinator from 2020 to 2021.
“It has been an honor to integrate and translate cutting edge technology to change the course of pandemics across the globe. Trained as a laboratory and clinical cellular immunologist I am excited to join the board of Nanolive SA, bringing my translational medicine and data driven expertise to this exciting technology. Nanolive innovation is critical to next generation cancer therapy, understanding the immune disruptions of long COVID, and ensuring a deeper understanding of host and pathogen interactions.”
Mrs. Victoria Wang is a Taiwanese American investment principal at Taiwania Capital with extensive experience in managing biotech investments and cultivating innovative technology in the life science and medical device industries. Having trained in innovation management and public health, Mrs. Wang focuses on discovering deep technology closer to environmental sustainability, making life science and medicine more inclusive to allow scientists and physicians to exploit rich biological information for impactful epidemiological data analysis.
“I have grown accustomed to discovering cutting-edge technologies and extraordinary talents in Switzerland from my past decades of experience as a senior executive of a Swiss/American life science company. Nanolive’s label-free live cell imaging technology and dynamic analysis solutions are revolutionizing cell biology which will accelerate drug discovery process and make cell-based therapies more quantifiable. I am very honored to be part of the board connecting Nanolive to many parts of the world.
About Nanolive
Nanolive SA is a Swiss company pioneer in the development and commercialization of innovative label-free, non-invasive live cell imaging and state-of-the-art digital analytical solutions. Nanolive’s breakthrough live-cell imaging and analysis platforms accelerate innovation in growth industries such as drug discovery and cell therapy. The Swiss company’s groundbreaking solutions combine screening, imaging, and analysis to radically advance how scientists study living cells and provide novel biological insights to longstanding questions in medicine such as the mechanisms involved in cancer and neurodegenerative diseases.
Being able to screen thousands of living cells in 3D, without damaging them promises to radically advance how scientists study living cells. But the quantitative analytical suite Nanolive offers is a complete game-changer. Combining sub-cellular resolution with unique AI-assisted digital assays provides researchers and scientists a unique opportunity to study complex cell-drug perturbation dynamics and cell-cell interactions (e.g., T cell and target cell interactions), quantitatively, an approach that will revolutionize the cell-based assay phase of the drug discovery workflow.
Source: Press Release